This paper demonstrates how assay data sets of a formulated liquid product, drug substance, and an impurity, obtained from combined accuracy-precision studies, are evaluated to calculate statistical intervals (prediction and tolerance intervals) and to graphically display the total analytical error (TAE) to account for the systematic and random errors.
QMM principles and practices can positively influence a sustainable drug supply and bolster the bottom-line of drug manufacturers, API suppliers, and CMO/CDMOs.
The event, cosponsored by FDA and USP, hosted regulators and industry leaders to discuss the challenges in strengthening the medical product supply chain.
The Supreme Court’s action leaves open the prospect of further rulings that could undermine FDA’s approval process.
Bob Girton, partner at Edgewater, discusses best practices for how pharma manufactures should incorporate sustainability into their operations.
AbbVie’s RINVOQ has received European Commission approval for the treatment of moderately to severely active Crohn’s disease.
Gamida Cell’s therapy is meant to reduce the risk of infection following stem cell transplantation.
FDA has granted fast track designation to Caribou Biosciences for its allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma.
A document signed by members of more than 400 companies and investment firms decries the decision made by a federal judge concerning mifepristone, a medication used in abortions.
Will court challenges to FDA’s oversight authority open the door for multiple lawsuits to block agency decisions on all sides?
The agency is dealing with high demand for staff because of a surge in the development of cell and gene therapies.
FDA aims to address mounting criticisms of its accelerated approval pathway.
Change management is central to the evolution of quality control laboratories, but what factors can maximize patient outcomes?
Impurities and batch-to-batch variability present the biggest challenges.
New child-friendly treatment options and initiatives are improving the outlook of children living with HIV in Europe.
FDA has spurred investment to create and develop 600 therapies.
Proposed regulatory changes signal a major overhaul of legislation governing pharmaceuticals and healthcare in Spain.
A risk assessment should be performed as part of the CAPA process, says Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates.
A further setback to the publication of the pharmaceutical legislative changes in Europe may mean time is running out for appropriate review before 2024 parliamentary elections.
FDA has approved Evkeeza for young children with homozygous familial hypercholesterolemia.
Takeda received approval in Japan for a subcutaneous injection formulation of Entyvio (vedolizumab) for treating ulcerative colitis.
Pierre Luzeau, CEO of Seqens, discusses Seqen's commitment to sustainability and how one can work toward it within their own company.
The Supreme Court heard oral arguments concerning the legitimacy of “genus clauses” in bio/pharma patents.
Narcan, from Emergent Solutions, will be the first naloxone product permitted for use without prescription by FDA.
A new Interagency Working Group for Bayh-Dole will review the government’s authority to revoke licenses for medical products.
